A recent study reveals that individuals who come off new weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who end conventional lifestyle regimens.
Research printed in a major medical journal points out that while obese individuals can lose substantial amounts of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.
"People buying such medications should be aware of the potential of rapid weight regain when the treatment ends," stated researcher Dr. Susan Jebb.
That rate of recovery means a reversion to original mass within about a year and a half.
Weighing Therapies
The analysis, which examined 37 of trials involving over 9,000 of participants, compared the effects of these new drugs with other pills.
The team emphasize that individuals who shed pounds through dieting usually experience a less rapid creep back—around 0.1 kg a month—post-intervention.
The Reason for the Rapid Regain
Doctors suggest the mechanism of the injections accounts for the accelerated weight return.
The injections imitate a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of the hormone levels several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous hormone, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' means appetite is no longer kept in check, making overeating a significant risk."
A Chronic Disease?
The NHS recommend the jabs for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, due to the significant potential of relapse, the treatment should be considered long-term.
This perspective is supported by drug manufacturers, who say that the results "highlight the chronic character of excess weight," comparing it to managing diseases like hypertension.
User Accounts
Users who have stopped the medication report a powerful resurgence of hunger.
"It was like a switch that goes on and you become ravenous," recalled a patient.
This challenge is compounded if patients have not developed permanent lifestyle or habit changes during treatment.
Growing Use
Recent estimates show that millions of adults in the UK have used these injections in the last 12 months, with demand remaining high.
- Use is higher among women than males.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
Ultimately, clinicians emphasize that while the jabs are effective agents for shedding pounds, they are not a standalone fix and maintained weight loss hinges on combined behavioural management.
